| Title | Chronic hepatitis B: treatment alert |
| Authors | Chang, Ting-Tsung Zhang, Hui Jia, Jidong Leung, Nancy Wai-Yee Guan, Richard Jafri, S. M. Wasim Lesmana, Laurentlus A. Liaw, Yun-Fan Locarnini, Stephen Omata, Masao Sollano, Jose D. Suh, Dong Jin Mahachai, Varocha Phiet, Pham Hoang Sarin, Shiv K. Yao, Guangbi Yoon, Seung Kew |
| Affiliation | Natl Cheng Kung Univ Hosp, Dept Med, Tainan 70428, Taiwan. Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing 100083, Peoples R China. Capital Univ Med Sci, Beijing Friendship Hosp, Liver Res Ctr, Beijing 100050, Peoples R China. Alice Ho Miu Ling Nethersole Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China. Natl Univ Singapore Hosp, Mt Elizabeth Med Ctr, Singapore 228510, Singapore. Aga Khan Univ, Karachi 3500, Pakistan. Univ Indonesia, Jakarta Dept Med, Jakarta 10350, Indonesia. Chang Gung Mem Hosp & Univ, Liver Res Unit, Taipei 105, Taiwan. Victorian Infect Dis Reference Lab, Melbourne, Vic 3051, Australia. Univ Tokyo, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan. Univ Santo Tomas Hosp, Manila 100864, Philippines. Asan Med Ctr, Seoul 138376, South Korea. Chulalongkorn Univ, GI Unit, Dept Med, Bangkok 10330, Thailand. Univ Med & Pharm, Dept Immunol & Physiopathol, Thanh Pho Ho Chi Minh, Vietnam. Catholic Univ Korea, Div Hepatogastroenterol, Div Internal Med, Kangnam St Marys Hosp, Seoul 137040, South Korea. Shanghai Jing An Qu Cent Hosp, Clin Immun Res Ctr, Shanghai 200040, Peoples R China. Univ Delhi, GB Pant Hosp, New Delhi 110002, India. Natl Cheng Kung Univ Hosp, Dept Med, 138 Sheng Li Rd, Tainan 70428, Taiwan. |
| Keywords | ALT levels consensus statement HBeAg negative HBeAg positive HBV DNA levels treatment guidelines ADEFOVIR DIPIVOXIL HEPATOCELLULAR-CARCINOMA VIRUS INFECTION LAMIVUDINE THERAPY UNITED-STATES LYMPHOBLASTOID INTERFERON PREEMPTIVE LAMIVUDINE CONSENSUS STATEMENT TREATMENT ALGORITHM POSITIVE PATIENTS |
| Issue Date | 2006 |
| Publisher | liver international |
| Citation | LIVER INTERNATIONAL.2006,26,47-58. |
| Abstract | Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of >= 20 000 IU/ml (>= 10(5) copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA >= 2000 IU/ml (>= 10(4) copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon alpha-2b, thymosin alpha-1, and, most recently, entecavir, and pegylated interferon alpha-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included. |
| URI | http://hdl.handle.net/20.500.11897/251241 |
| ISSN | 1478-3223 |
| DOI | 10.1111/j.1478-3231.2006.01374.x |
| Indexed | SCI(E) |
| Appears in Collections: | 医学部待认领 |
